Cargando…

Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy

This study aimed to evaluate the prognosis of breast cancer patients who received neoadjuvant chemotherapy and underwent sentinel lymph node biopsy (SLNB) alone as axillary surgery regardless of their clinical and pathological lymph node status. We reviewed the records of 1,795 patients from Asan Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sae Byul, Kim, Hakyoung, Kim, Jisun, Chung, Il Yong, Kim, Hee Jeong, Ko, Beom Seok, Lee, Jong Won, Ahn, Sei Hyun, Son, Byung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130919/
https://www.ncbi.nlm.nih.gov/pubmed/34003871
http://dx.doi.org/10.1371/journal.pone.0251597
_version_ 1783694608328294400
author Lee, Sae Byul
Kim, Hakyoung
Kim, Jisun
Chung, Il Yong
Kim, Hee Jeong
Ko, Beom Seok
Lee, Jong Won
Ahn, Sei Hyun
Son, Byung Ho
author_facet Lee, Sae Byul
Kim, Hakyoung
Kim, Jisun
Chung, Il Yong
Kim, Hee Jeong
Ko, Beom Seok
Lee, Jong Won
Ahn, Sei Hyun
Son, Byung Ho
author_sort Lee, Sae Byul
collection PubMed
description This study aimed to evaluate the prognosis of breast cancer patients who received neoadjuvant chemotherapy and underwent sentinel lymph node biopsy (SLNB) alone as axillary surgery regardless of their clinical and pathological lymph node status. We reviewed the records of 1,795 patients from Asan Medical Center who were diagnosed with stage I–III breast cancer and received neoadjuvant chemotherapy during 2003–2014. We selected 760 patients who underwent SLNB alone as axillary surgery and divided these patients into four groups according to their clinical lymph node (cN) and pathological lymph node (pN) status: cN(-)pN(-) (n = 377), cN(-)pN(+) (n = 33), cN(+)pN(-) (n = 242), and cN(+)pN(+) (n = 108). We then compared axillary lymph node recurrence, locoregional recurrence (LRR), distant metastasis-free survival (DMFS), and overall survival (OS) among the four groups using Kaplan–Meier analysis. We compared prognosis between the cN(-)pN(-) and cN(+)pN(-) groups to determine whether SLNB alone is an adequate treatment modality even in patients with cN positive pathology before neoadjuvant therapy but SLNB-negative pathology after NAC. The 5-year axillary recurrence rates in the cN(-)pN(-) and cN(+)pN(-) groups were 1.4% and 2.9%, respectively, and there was no significant difference between the two groups (p = 0.152). The axillary recurrence and LRR rates were significantly different among the four groups, with the pN-negative groups (cN[–]pN[–], cN[+]pN[–]) showing lower recurrence rates. DMFS and OS were also significantly different among the four groups, with the cN negative groups (cN[–]pN[–], cN[–]pN[+]) showing improved survival rates. Our study findings suggest that SLNB alone was associated with lower LRR rates even in patients with cN positive pathology before neoadjuvant therapy but cN negative pathology after SLNB. Moreover, recurrence and survival rates differ significantly according to clinical and pathological lymph node status.
format Online
Article
Text
id pubmed-8130919
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-81309192021-05-27 Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy Lee, Sae Byul Kim, Hakyoung Kim, Jisun Chung, Il Yong Kim, Hee Jeong Ko, Beom Seok Lee, Jong Won Ahn, Sei Hyun Son, Byung Ho PLoS One Research Article This study aimed to evaluate the prognosis of breast cancer patients who received neoadjuvant chemotherapy and underwent sentinel lymph node biopsy (SLNB) alone as axillary surgery regardless of their clinical and pathological lymph node status. We reviewed the records of 1,795 patients from Asan Medical Center who were diagnosed with stage I–III breast cancer and received neoadjuvant chemotherapy during 2003–2014. We selected 760 patients who underwent SLNB alone as axillary surgery and divided these patients into four groups according to their clinical lymph node (cN) and pathological lymph node (pN) status: cN(-)pN(-) (n = 377), cN(-)pN(+) (n = 33), cN(+)pN(-) (n = 242), and cN(+)pN(+) (n = 108). We then compared axillary lymph node recurrence, locoregional recurrence (LRR), distant metastasis-free survival (DMFS), and overall survival (OS) among the four groups using Kaplan–Meier analysis. We compared prognosis between the cN(-)pN(-) and cN(+)pN(-) groups to determine whether SLNB alone is an adequate treatment modality even in patients with cN positive pathology before neoadjuvant therapy but SLNB-negative pathology after NAC. The 5-year axillary recurrence rates in the cN(-)pN(-) and cN(+)pN(-) groups were 1.4% and 2.9%, respectively, and there was no significant difference between the two groups (p = 0.152). The axillary recurrence and LRR rates were significantly different among the four groups, with the pN-negative groups (cN[–]pN[–], cN[+]pN[–]) showing lower recurrence rates. DMFS and OS were also significantly different among the four groups, with the cN negative groups (cN[–]pN[–], cN[–]pN[+]) showing improved survival rates. Our study findings suggest that SLNB alone was associated with lower LRR rates even in patients with cN positive pathology before neoadjuvant therapy but cN negative pathology after SLNB. Moreover, recurrence and survival rates differ significantly according to clinical and pathological lymph node status. Public Library of Science 2021-05-18 /pmc/articles/PMC8130919/ /pubmed/34003871 http://dx.doi.org/10.1371/journal.pone.0251597 Text en © 2021 Lee et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lee, Sae Byul
Kim, Hakyoung
Kim, Jisun
Chung, Il Yong
Kim, Hee Jeong
Ko, Beom Seok
Lee, Jong Won
Ahn, Sei Hyun
Son, Byung Ho
Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
title Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
title_full Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
title_fullStr Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
title_full_unstemmed Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
title_short Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
title_sort prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130919/
https://www.ncbi.nlm.nih.gov/pubmed/34003871
http://dx.doi.org/10.1371/journal.pone.0251597
work_keys_str_mv AT leesaebyul prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT kimhakyoung prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT kimjisun prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT chungilyong prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT kimheejeong prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT kobeomseok prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT leejongwon prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT ahnseihyun prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy
AT sonbyungho prognosisaccordingtoclinicalandpathologiclymphnodestatusinbreastcancerpatientswhounderwentsentinellymphnodebiopsyaloneafterneoadjuvanttherapy